Common errors, pitfalls, and management of complications of prostate biopsy The most common diagnostic and procedural challenges of transrectal fusion prostate biopsy in the initial diagnosis of clinically significant prostate cancer

被引:0
|
作者
Enzinger, Benazir [1 ]
Pfitzinger, Paulo Leonardo [1 ]
Ebner, Benedikt [1 ]
Ivanova, Troya [1 ]
Volz, Yannic [1 ]
Apfelbeck, Maria [1 ]
Kazmierczak, Philipp [2 ]
Stief, Christian [1 ]
Chaloupka, Michael [1 ]
机构
[1] LMU Klinikum, Urol Klin & Poliklin, Marchioninistr 15, D-81377 Munich, Germany
[2] LMU Klinikum, Klinik & Poliklin Radiol, Marchioninistr 15, D-81377 Munich, Germany
来源
UROLOGIE | 2023年 / 62卷 / 05期
关键词
Prostate cancer; Risk stratification; Fusion biopsy; Transperineal approach; Infections; ULTRASOUND-GUIDED BIOPSY; INFECTIOUS COMPLICATIONS; RISK CALCULATOR; ACCURACY;
D O I
10.1007/s00120-023-02063-y
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Transrectal (TR) prostate biopsy is the gold standard in diagnosis of prostate cancer (PC). It requires a precise and safe technique for sample acquisition.Objective: Several approaches will be discussed to avoid overdiagnosis, false-negative results, and complications of the procedure.Materials and methods: We analyzed national and European guidelines, systematic reviews, meta-analyses, as well as prospective and retrospective studies to describe current trends in indication and performance of biopsies.Results: Incorporation of risk calculators and magnetic resonance imaging (MRI) into daily routine reduces biopsy rates and results in a more precise diagnosis of clinically significant prostate cancer (csPC). Combination of random- and MRI-fusion guided biopsy-but also extending the radius of sampling by 10 mm beyond the MRI lesion and a transperineal (TP) sampling approach - lead to a higher tumor-detection rate. Bleeding is the most common complication after prostate biopsy and is usually self-limiting. Postbiopsy infection rates can be reduced through TP biopsy.Conclusion: TR MRI-fusion guided biopsy is a widely acknowledged tool in primary diagnostics of csPC. Higher detection rates and safety can be achieved through a TP sampling approach.
引用
收藏
页码:479 / 486
页数:8
相关论文
共 50 条
  • [41] Precision of MRI/ultrasound-fusion biopsy in prostate cancer diagnosis: an ex vivo comparison of alternative biopsy techniques on prostate phantoms
    N. Westhoff
    F. P. Siegel
    D. Hausmann
    M. Polednik
    J. von Hardenberg
    M. S. Michel
    M. Ritter
    World Journal of Urology, 2017, 35 : 1015 - 1022
  • [42] New Diagnostic Model for Clinically Significant Prostate Cancer in Biopsy-Naive Men With PIRADS 3
    Huang, Chen
    Qiu, Feng
    Jin, Di
    Wei, Xuedong
    Chen, Zongxin
    Wang, Ximing
    Zhao, Xiaojun
    Guo, Linchuan
    Pu, Jinxian
    Hou, Jianquan
    Huang, Yuhua
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [43] A Prospective Comparison of Transrectal Standard, Cognitive, Transperineal Fusion, and Mapping Prostate Biopsy for Cancer Detection
    Petov, Vladislav
    Bazarkin, Andrey
    Morozov, Andrey
    Taratkin, Mark
    Ganzha, Timur
    Danilov, Sergey
    Chernov, Yaroslav
    Chinenov, Denis
    Rzayev, Ramin
    Suvorov, Alexander
    Amosov, Alexander
    Fajkovic, Harun
    Enikeev, Dmitry
    Krupinov, German
    JOURNAL OF ENDOUROLOGY, 2023, 37 (08) : 940 - 947
  • [44] Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsy
    Brembilla, Giorgio
    Lavalle, Salvatore
    Parry, Tom
    Cosenza, Michele
    Russo, Tommaso
    Mazzone, Elio
    Pellegrino, Francesco
    Stabile, Armando
    Gandaglia, Giorgio
    Briganti, Alberto
    Montorsi, Francesco
    Esposito, Antonio
    De Cobelli, Francesco
    EUROPEAN JOURNAL OF RADIOLOGY, 2023, 164
  • [45] Comparative diagnostic accuracy of multiparametric magnetic resonance imaging-ultrasound fusion-guided biopsy versus systematic biopsy for clinically significant prostate cancer
    Fang, Jian-hua
    Zhang, Liqing
    Xie, Xi
    Zhao, Pan
    Bao, Lingyun
    Kong, Fanlei
    PEERJ, 2023, 11
  • [46] Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3-5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate
    Szemplinski, Stanislaw
    Kamecki, Hubert
    Debowska, Malgorzata
    Zagozdzon, Bartlomiej
    Mokrzys, Mateusz
    Zawadzki, Marek
    Sosnowski, Roman
    Tokarczyk, Andrzej
    Poletajew, Slawomir
    Kryst, Piotr
    Nyk, Lukasz
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (01)
  • [47] Detection of clinically significant prostate cancer by transperineal multiparametric magnetic resonance imaging-ultrasound fusion targeted prostate biopsy in smaller prostates
    Dahl, Douglas M.
    Kim, Michelle M.
    Wu, Shulin
    Lin, Sharron X.
    Crotty, Rory K.
    Cornejo, Kristine M.
    Harisinghani, Mukesh G.
    Feldman, Adam S.
    Wu, Chin-Lee
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (10) : 451.e9 - 451.e14
  • [48] Superior detection of significant prostate cancer by transperineal prostate biopsy using MRI-transrectal ultrasound fusion image guidance over cognitive registration
    Ito, Masaya
    Yonese, Ichiro
    Toide, Masahiro
    Ikuta, Shuzo
    Kobayashi, Shuichiro
    Koga, Fumitaka
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (11) : 1545 - 1553
  • [49] Superior detection of significant prostate cancer by transperineal prostate biopsy using MRI-transrectal ultrasound fusion image guidance over cognitive registration
    Masaya Ito
    Ichiro Yonese
    Masahiro Toide
    Shuzo Ikuta
    Shuichiro Kobayashi
    Fumitaka Koga
    International Journal of Clinical Oncology, 2023, 28 : 1545 - 1553
  • [50] Rate of clinically significant prostate cancer on repeated biopsy after a diagnosis of atypical small acinar proliferation
    Yazdani, Mohammad
    Samani, Payam Riahi
    Mazdak, Hamid
    Yazdani, Amid
    IMMUNOPATHOLOGIA PERSA, 2023, 9 (01):